secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001411690-25-000003
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano reports preliminary Q4 rev $7.9-8.1M (down ~25% YoY); FY rev $30.5-30.7M (down ~15%)
--------------------------------------------------------------------------------

- Preliminary Q4 2024 revenue $7.9-8.1M, down ~25% from Q4 2023 due to discontinued clinical service products.
- Full year 2024 revenue $30.5-30.7M, down ~15% from FY2023; excluding discontinued services, core revenue ~$29M, roughly flat.
- OGM installed base 371 units at year-end, up 14% from 326 at end of 2023; flowcell sales 8,058, up 1% YoY.
- Cash, equivalents and AFS securities $20.9M as of Dec 31, 2024; raised $10M gross via registered direct offering in Jan 2025.
- Annualized operating costs reduced by ~$100M since May 2023; senior secured convertible debenture terms modified to lower monthly payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000141169025000003/0001411690-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000141169025000003/bngo-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001411690-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer